4.7 Article

Neurofilament Levels as Biomarkers in Asymptomatic and Symptomatic Familial Amyotrophic Lateral Sclerosis

Journal

ANNALS OF NEUROLOGY
Volume 79, Issue 1, Pages 152-158

Publisher

WILEY
DOI: 10.1002/ana.24552

Keywords

-

Funding

  1. Federal Ministry of Education and Research, Germany
  2. MND-Net
  3. Virtual Helmholtz-Institute on RNA Dysmetabolism
  4. Competence Net Neurodegenerative Dementias (project: FTLDc)
  5. EU Joint Programme - Neurodegenerative Disease (JPND) Research Networks for Standardization of Biomarkers (BiomarkAPD, Sophia) and Prefrontals
  6. European Union (NADINE)
  7. foundation of the state of Baden-Wurttemberg
  8. Thierry Latran Foundation
  9. Federal Ministry for Economic Affairs and Energy
  10. BIU

Ask authors/readers for more resources

Neurofilaments are elevated in the cerebrospinal fluid (CSF) and serum of amyotrophic lateral sclerosis (ALS) patients. However, timing of this increase is unknown. To characterize the premanifest disease phase, we performed a cross-sectional study on asymptomatic (n=12) and symptomatic (n=64) ALS mutation carriers and family controls (n=19). Neurofilaments NF-L (neurofilament-light chain) and pNF-H (phosphorylated neurofilament-heavy chain) are normal before symptom onset and increased by at least an order of magnitude at early symptom onset in CSF (pNF-H) or serum and CSF (NF-L). Thus, blood and CSF neurofilament levels are linked to the symptomatic phase of ALS and might serve as objective markers of structural damage to the nervous system.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available